Several studies have investigated the impact of ApoA1 genetic polymorphisms on dyslipidemia and CVD risks, but the considerable effect of ApoA1 polymorphisms among different ethnic populations and their association with the risk of arterial stiffness in older people was limited. This evidence concerns the gene APOA1 and metabolic syndrome.